The Private Market for TB Drugs: Big and Messy, but a Necessary Partner in Stopping the TB Epidemic TB treatment is widely considered a public sector responsibility. But, a new TB Alliance study published in PLoS ONE, indicates the private market is larger than previously thought and highly fragmented.
click for more information Click here to watch a video summarizing the findings
1 | 2 | 3 | 4 | 5 | 6 |
 
What We Do The TB Alliance is a not-for-profit, product development partnership accelerating the discovery and development of new TB drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB patients currently on such therapies, and improve treatment of latent infection. The TB Alliance is committed to ensuring that approved new drug regimens are affordable, widely adopted and available to those who need them.

  
Our Portfolio Working with public and private partners worldwide, the TB Alliance is leading the development of the most comprehensive portfolio in history of TB drug candidates for the treatment and cure of tuberculosis, a disease that kills someone every twenty seconds.


Take Action The TB Alliance is seeking help to ensure that it can continue developing new, faster and better TB drugs that are affordable and accessible to those who need them.

You can help.

click to find out what you can do
Career Opportunities The TB Alliance is seeking qualified candidates to join our global team. Please click here to view current openings.
 
Find Out More
View our Latest Newsletter
> click here
Our 2010 Annual Report
> download
> request a copy
Why the world needs new TB Drugs (.pdf - 94kb)
> click here
Sign up to receive our latest news
header